121 related articles for article (PubMed ID: 36657279)
1. Genetic analysis of IMPDH2 gene in Taiwanese patients with isolated or combined dystonia.
Chen PS; Wu MC; Tai CH; Chang YY; Lan MY; Chen YF; Lin HI; Lee NC; Lin CH
Parkinsonism Relat Disord; 2023 Feb; 107():105294. PubMed ID: 36657279
[TBL] [Abstract][Full Text] [Related]
2. Rare variants in IMPDH2 cause autosomal dominant dystonia in Chinese population.
Lin J; Li C; Cui Y; Hou Y; Zhang L; Ou R; Wei Q; Liu K; Yang T; Xiao Y; Jiang Q; Zhao B; Yang J; Chen X; Shang H
J Neurol; 2023 Apr; 270(4):2197-2203. PubMed ID: 36648520
[TBL] [Abstract][Full Text] [Related]
3. IMPDH2: a new gene associated with dominant juvenile-onset dystonia-tremor disorder.
Kuukasjärvi A; Landoni JC; Kaukonen J; Juhakoski M; Auranen M; Torkkeli T; Velagapudi V; Suomalainen A
Eur J Hum Genet; 2021 Dec; 29(12):1833-1837. PubMed ID: 34305140
[TBL] [Abstract][Full Text] [Related]
4. Neurodevelopmental disorder mutations in the purine biosynthetic enzyme IMPDH2 disrupt its allosteric regulation.
O'Neill AG; Burrell AL; Zech M; Elpeleg O; Harel T; Edvardson S; Mor-Shaked H; Rippert AL; Nomakuchi T; Izumi K; Kollman JM
J Biol Chem; 2023 Aug; 299(8):105012. PubMed ID: 37414152
[TBL] [Abstract][Full Text] [Related]
5. A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity.
Wang J; Zeevi A; Webber S; Girnita DM; Addonizio L; Selby R; Hutchinson IV; Burckart GJ
Pharmacogenet Genomics; 2007 Apr; 17(4):283-90. PubMed ID: 17496727
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics.
Wu TY; Peng Y; Pelleymounter LL; Moon I; Eckloff BW; Wieben ED; Yee VC; Weinshilboum RM
Br J Pharmacol; 2010 Dec; 161(7):1584-98. PubMed ID: 20718729
[TBL] [Abstract][Full Text] [Related]
7. Interpopulation variation frequency of human inosine 5'-monophosphate dehydrogenase type II (IMPDH2) genetic polymorphisms.
Mohamed MF; Frye RF; Langaee TY
Genet Test; 2008 Dec; 12(4):513-6. PubMed ID: 18976158
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of inosine 5'-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cells.
Fellenberg J; Kunz P; Sähr H; Depeweg D
PLoS One; 2010 Aug; 5(8):e12179. PubMed ID: 20808934
[TBL] [Abstract][Full Text] [Related]
9. Point mutations in IMPDH2 which cause early-onset neurodevelopmental disorders disrupt enzyme regulation and filament structure.
O'Neill AG; Burrell AL; Zech M; Elpeleg O; Harel T; Edvardson S; Shaked HM; Rippert AL; Nomakuchi T; Izumi K; Kollman JM
bioRxiv; 2023 Mar; ():. PubMed ID: 36993700
[TBL] [Abstract][Full Text] [Related]
10. Assignment1 of inosine '-monophosphate dehydrogenase type 2 (IMPDH2) to human chromosome band 3p21.2 by in situ hybridization.
Kost-Alimova MV; Glesne DA; Huberman E; Zelenin AV
Cytogenet Cell Genet; 1998; 82(3-4):145-6. PubMed ID: 9858805
[No Abstract] [Full Text] [Related]
11. High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma.
Xu Y; Zheng Z; Gao Y; Duan S; Chen C; Rong J; Wang K; Yun M; Weng H; Ye S; Zhang J
Sci Rep; 2017 Apr; 7(1):745. PubMed ID: 28389646
[TBL] [Abstract][Full Text] [Related]
12. Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer.
Zhou L; Xia D; Zhu J; Chen Y; Chen G; Mo R; Zeng Y; Dai Q; He H; Liang Y; Jiang F; Zhong W
Clin Transl Oncol; 2014 Oct; 16(10):906-13. PubMed ID: 24659377
[TBL] [Abstract][Full Text] [Related]
13. IMPDH2 forms spots at branching sites and distal ends of astrocyte stem processes.
Toyoda S; Handa T; Yong H; Takahashi H; Shiwaku H
Genes Cells; 2024 Feb; 29(2):150-158. PubMed ID: 38009721
[TBL] [Abstract][Full Text] [Related]
14. Silencing of hepsin and inosine 5-monophosphate dehydrogenase 2 by siRNA reduces prostate cancer cells proliferation.
A Wahab N; D Dardar H; Yunus R; M Zainudin Z; M Mokhtar N
Malays J Pathol; 2022 Apr; 44(1):29-38. PubMed ID: 35484884
[TBL] [Abstract][Full Text] [Related]
15. IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways.
Duan S; Huang W; Liu X; Liu X; Chen N; Xu Q; Hu Y; Song W; Zhou J
J Exp Clin Cancer Res; 2018 Dec; 37(1):304. PubMed ID: 30518405
[TBL] [Abstract][Full Text] [Related]
16. Development of a recombinant cell-based indirect immunofluorescence assay (RC-IFA) for the determination of autoantibodies against "rings and rods"-associated inosine-5'-monophosphate dehydrogenase 2 in viral hepatitis C.
Probst C; Radzimski C; Blöcker IM; Teegen B; Bogdanos DP; Stöcker W; Komorowski L
Clin Chim Acta; 2013 Mar; 418():91-6. PubMed ID: 23333419
[TBL] [Abstract][Full Text] [Related]
17. IMPDH2 genetic polymorphism: a promoter single-nucleotide polymorphism disrupts a cyclic adenosine monophosphate responsive element.
Garat A; Cauffiez C; Hamdan-Khalil R; Glowacki F; Devos A; Leclerc J; Lionet A; Allorge D; Lo-Guidice JM; Broly F
Genet Test Mol Biomarkers; 2009 Dec; 13(6):841-7. PubMed ID: 19810816
[TBL] [Abstract][Full Text] [Related]
18. Chromosomal localization and structure of the human type II IMP dehydrogenase gene (IMPDH2).
Glesne D; Collart F; Varkony T; Drabkin H; Huberman E
Genomics; 1993 Apr; 16(1):274-7. PubMed ID: 8098009
[TBL] [Abstract][Full Text] [Related]
19. An inosine 5'-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid.
Winnicki W; Weigel G; Sunder-Plassmann G; Bajari T; Winter B; Herkner H; Sengoelge G
Pharmacogenomics J; 2010 Feb; 10(1):70-6. PubMed ID: 19770842
[TBL] [Abstract][Full Text] [Related]
20. Ultrastructure of cytoplasmic and nuclear inosine-5'-monophosphate dehydrogenase 2 "rods and rings" inclusions.
Juda P; Smigová J; Kováčik L; Bártová E; Raška I
J Histochem Cytochem; 2014 Oct; 62(10):739-50. PubMed ID: 24980853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
